Equities Analysts Issue Forecasts for TSHA FY2025 Earnings

Key Points

• Chardan Capital has issued a FY2025 earnings forecast for Taysha Gene Therapies, estimating an earnings per share of ($0.31), with a Buy rating and a price objective of $10.00.
• Taysha Gene Therapies reported a quarterly earnings of ($0.09) per share, missing the consensus estimate, while achieving revenue of $1.99 million.
• Insider activity shows major shareholder Paul B. Manning acquired 750,000 shares at an average price of $2.75, increasing his ownership in the company by 35.86%.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Investment analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Taysha Gene Therapies in a research note issued on Wednesday, August 13th. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings per share of ($0.31) for the year. Chardan Capital has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.

Several other research analysts have also weighed in on the stock. JMP Securities raised their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a report on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Canaccord Genuity Group increased their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Finally, Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.29.

Taysha Gene Therapies Stock Up 4.5%

TSHA stock traded up $0.13 during mid-day trading on Monday, hitting $3.00. 9,089,763 shares of the company were exchanged, compared to its average volume of 2,568,445. The company has a market capitalization of $643.99 million, a PE ratio of -8.82 and a beta of 0.98. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $3.31. The firm has a fifty day simple moving average of $2.63 and a 200 day simple moving average of $2.16.

Insider Buying and Selling at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning acquired 750,000 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the acquisition, the insider directly owned 2,841,704 shares in the company, valued at approximately $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.78% of the stock is currently owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Large investors have recently modified their holdings of the company. LPL Financial LLC acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth about $104,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth about $8,650,000. Hsbc Holdings PLC increased its holdings in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after acquiring an additional 8,076 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth about $41,000. Finally, Millennium Management LLC acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth about $262,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.